SIRPα blockade therapy inhibited SIRPα/CD47 axis-mediated PI3K/AKT signaling to suppress migration, PD-L1 expression of myeloid cells in vitro and HCC progression. The gene discussed is AKT1; the disease is hepatocellular carcinoma.